Loading clinical trials...

Inhaled NAC in Treatment of IPF | Clinical Trials | Clareo Health

WITHDRAWNPHASE1/PHASE2

Inhaled NAC in Treatment of IPF

Pilot Study to Evaluate Inhaled N-Acetylcysteine in Pulmonary Fibrosis

NCT03720483•University of Colorado, Denver

View on ClinicalTrials.gov

Summary

Detailed Description

This study plans to learn more about the safety and tolerability of inhaled N-Acetylcysteine (NAC) in patients with pulmonary fibrosis. The study will also create a bank of data, blood, and sputum from IPF patients for future research. NAC is a medication used to loosen thick mucus. NAC was initially licensed for use in 1968. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system, and it is available as a generic medication and is not very expensive. Inhaled NAC has been used as a mucus-dissolving therapy in respiratory conditions with excessive and/or thick mucus production.

Eligibility

Age

40 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosed by study team with expertise in IPF utilizing standard ATS/ERS definition of "probable" or "definite" IPF
•DLCO \>50% predicted
•FVC \>60% predicted
•FEV1/FVC \> 0.7

Exclusion Criteria

•History of bronchospasm (requiring treatment)
•Current acute exacerbation of their IPF disease
•Current smoker
•Supplemental O2 requirement \> 4 liters/min via nasal cannula
•History of asthma, COPD, coronary artery disease, or cancer
•Currently using NAC, hypertonic saline, or DNase (dornase alfa) inhalation therapy

Locations (1)

University of Colorado Anschutz Medical Campus

Aurora, Colorado, United States

Key Dates

Start Date

January 1, 2022

Primary Completion Date

December 1, 2023

Completion Date

December 1, 2023

Last Updated

June 8, 2021

Conditions

Idiopathic Pulmonary Fibrosis (IPF)

Interventions

N-acetyl cysteine then Placebo

DRUG

Placebo then N-acetyl cysteine

DRUG

Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.

NCT07466420

Fibrotic Interstitial Lungs DiseasesIdiopathic Pulmonary Fibrosis (IPF)+1 more

View study

ACTIVE_NOT_RECRUITINGPHASE1/PHASE2

Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis

NCT04598919

Idiopathic Pulmonary Fibrosis (IPF)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 8, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Inhaled NAC in Treatment of IPF

Inclusion Criteria

Exclusion Criteria

Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.

Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis

Perioperative Risk Factors Related to the Prognosis of Lung Transplantation: A Retrospective Study

Comparison of the Efficacy of Pirfenidone and Nintedanipine in Pulmonary Fibrosis

Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis

To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy Volunteers